Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Case Comprehensive Cancer Center
With
OBJECTIVES: * Determine the maximum tolerated dose and safety of SU5416 and paclitaxel in patients with recurrent or metastatic head and neck cancer. * Determine the antiangiogenesis effect of this combination regimen in these patients. * Determine the toxicity, pharmacodynamic effects, and pharmacokinetic parameters of this combination. OUTLINE: This is a dose escalation study. Patients receive paclitaxel IV over one hour on day 1 and SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of paclitaxel and SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose limiting toxicities. PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study within 9-15 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
